<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328599</url>
  </required_header>
  <id_info>
    <org_study_id>COV EES-14606</org_study_id>
    <secondary_id>U01DK114156</secondary_id>
    <nct_id>NCT02328599</nct_id>
  </id_info>
  <brief_title>Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes</brief_title>
  <acronym>ARMMS-T2D</acronym>
  <official_title>A Prospective Consortium Evaluating the Long-term Follow-up of Patients With Type 2 Diabetes Enrolled In a Randomized Controlled Trial Comparing Bariatric Surgery Versus Medical Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initially, 4 teams of investigators conducted randomized controlled trials (RCT) at their own
      site to evaluate the effectiveness of bariatric surgery compared to medical/lifestyle
      management of type 2 diabetes. Each study followed subjects for a duration of about 1 - 3
      years. Following this, a consortium was created to pool data and continue to follow study
      participants. This early collaboration of the 4 groups of investigators was supported by
      Industry sponsors (Ethicon, Inc and Medtronic-MITG). Now, the investigators have successfully
      received a grant from the NIH, as the sole supporter of continued observational follow-up of
      study participants.

      The continuing aim of this study is to combine data from the 4 studies and follow the
      original randomized subjects for an additional 5 years of follow-up. The purpose of the study
      is to determine the longer term durability and effectiveness of bariatric surgery compared to
      medical/lifestyle intervention on the treatment of type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The four investigative groups initiated their individual RCT's at their respective sites to
      evaluate the effectiveness of bariatric surgery compared to multidisciplinary medical and
      lifestyle management of diabetes and body weight. The original trials were each designed to
      assess feasibility over a relatively short duration of follow-up (1-3 years). Individually,
      each trial lacked the sample size and duration of follow-up to meaningfully inform clinical
      decision making. Together, with the funding provided by the NIH for longer follow-up, the
      Consortium trial can provide a unique national resource to address timely and unanswered
      clinical questions related to the durability of these alternative management approaches in
      patients with T2D and obesity. Together, participants from these studies represent the
      largest cohort with diabetes (one third having a BMI &lt;35 kg/m2) ever to undergo randomized
      assignment to bariatric surgical procedure vs. medical/lifestyle intervention.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of biochemical resolution of diabetes</measure>
    <time_frame>7 years</time_frame>
    <description>Biochemical resolution of diabetes measured by HbA1c &lt;/= 6.5%, without diabetes medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term diabetes control</measure>
    <time_frame>7 years and each annual visit through the last known follow-up for all patients</time_frame>
    <description>Mean and change from baseline in HbA1c</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">302</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Surgical</arm_group_label>
    <description>Prior Bariatric surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical</arm_group_label>
    <description>Medical / Lifestyle management</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery involving Roux-en-Y gastric bypass</intervention_name>
    <description>Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.</description>
    <arm_group_label>Surgical</arm_group_label>
    <other_name>RYGB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery involving Laparoscopic adjustable gastric banding</intervention_name>
    <description>Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.</description>
    <arm_group_label>Surgical</arm_group_label>
    <other_name>LAGB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery involving Laparoscopic sleeve gastrectomy</intervention_name>
    <description>Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.</description>
    <arm_group_label>Surgical</arm_group_label>
    <other_name>LSG</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Study specific blood and urine specimens will be analyzed at a central laboratory.
      Participation in the research repository is optional. Blood will be drawn and stored at each
      site for later analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who were previously enrolled in a Randomized Control Trial (RCT) at one of the
        four participating sites who initiated one of the intervention procedures - bariatric
        surgery or medical/lifestyle therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Original inclusion criteria for participation in the RCTs at all sites included:

               -  Candidate for general anesthesia or unsupervised exercise.

               -  Age ≥20 and ≤65 years.

               -  Body mass index &gt;27 and ≤45 kg/m2.

               -  Diagnosis of type 2 diabetes confirmed by either requiring diabetes medication
                  and/or having elevated glycemia based on HbA1c, fasting plasma glucose, and/or
                  oral glucose tolerance test (OGTT) results, according to American Diabetes
                  Association criteria.

               -  Ability and willingness to participate in the study and agree to any of the
                  research arms.

               -  Able to understand the options and to comply with the requirements of each
                  program.

               -  Negative urine pregnancy test at screening and baseline visits (prior to surgery)
                  for women of childbearing potential (i.e., biologically capable of becoming
                  pregnant).

        Exclusion Criteria:

          -  Subjects who were randomized in one of the four RCTs but never initiated intervention
             / did not receive randomized treatment

          -  Refusal to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip R Schauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Kirwan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Bariatric and Metabolic Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753-61.</citation>
    <PMID>17715409</PMID>
  </reference>
  <reference>
    <citation>Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004 Oct 13;292(14):1724-37. Review. Erratum in: JAMA. 2005 Apr 13;293(14):1728.</citation>
    <PMID>15479938</PMID>
  </reference>
  <reference>
    <citation>Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004 Dec 23;351(26):2683-93.</citation>
    <PMID>15616203</PMID>
  </reference>
  <reference>
    <citation>Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009 Mar;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041. Review.</citation>
    <PMID>19272486</PMID>
  </reference>
  <reference>
    <citation>Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I, Pirazzi C, Romeo S, Sjöholm K, Sjöström E, Wedel H, Svensson PA, Sjöström L. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012 Aug 23;367(8):695-704. doi: 10.1056/NEJMoa1112082.</citation>
    <PMID>22913680</PMID>
  </reference>
  <reference>
    <citation>Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995 Sep;222(3):339-50; discussion 350-2.</citation>
    <PMID>7677463</PMID>
  </reference>
  <reference>
    <citation>Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003 Oct;238(4):467-84; discussion 84-5.</citation>
    <PMID>14530719</PMID>
  </reference>
  <reference>
    <citation>Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393-411. doi: 10.1146/annurev.med.051308.105148. Review.</citation>
    <PMID>20059345</PMID>
  </reference>
  <reference>
    <citation>Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, Kashyap SR, Kirwan JP, Rogula T, Kroh M, Chand B, Schauer PR. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013 Oct;258(4):628-36; discussion 636-7. doi: 10.1097/SLA.0b013e3182a5034b.</citation>
    <PMID>24018646</PMID>
  </reference>
  <reference>
    <citation>Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008 Jan 23;299(3):316-23. doi: 10.1001/jama.299.3.316.</citation>
    <PMID>18212316</PMID>
  </reference>
  <reference>
    <citation>Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26;366(17):1567-76. doi: 10.1056/NEJMoa1200225. Epub 2012 Mar 26.</citation>
    <PMID>22449319</PMID>
  </reference>
  <reference>
    <citation>Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012 Apr 26;366(17):1577-85. doi: 10.1056/NEJMoa1200111. Epub 2012 Mar 26.</citation>
    <PMID>22449317</PMID>
  </reference>
  <reference>
    <citation>Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013 Jun 5;309(21):2240-9. doi: 10.1001/jama.2013.5835.</citation>
    <PMID>23736733</PMID>
  </reference>
  <reference>
    <citation>Halperin F, Ding SA, Simonson DC, Panosian J, Goebel-Fabbri A, Wewalka M, Hamdy O, Abrahamson M, Clancy K, Foster K, Lautz D, Vernon A, Goldfine AB. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):716-26. doi: 10.1001/jamasurg.2014.514.</citation>
    <PMID>24899464</PMID>
  </reference>
  <reference>
    <citation>Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, Toledo FG, Jakicic JM. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):707-15. doi: 10.1001/jamasurg.2014.467.</citation>
    <PMID>24899268</PMID>
  </reference>
  <reference>
    <citation>Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, O'Connor PJ, Theis MK, Campos GM, McCulloch D, Selby J. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013 Jan;23(1):93-102. doi: 10.1007/s11695-012-0802-1.</citation>
    <PMID>23161525</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Flum DR. Gastrointestinal surgery as a treatment for diabetes. JAMA. 2008 Jan 23;299(3):341-3. doi: 10.1001/jama.299.3.341.</citation>
    <PMID>18212321</PMID>
  </reference>
  <reference>
    <citation>Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006 Nov;244(5):741-9.</citation>
    <PMID>17060767</PMID>
  </reference>
  <reference>
    <citation>Zimmet P, Alberti KG, Rubino F, Dixon JB. IDF's view of bariatric surgery in type 2 diabetes. Lancet. 2011 Jul 9;378(9786):108-10. doi: 10.1016/S0140-6736(11)61027-1.</citation>
    <PMID>21742162</PMID>
  </reference>
  <reference>
    <citation>Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden Å, Bengtsson C, Bergmark G, Bouchard C, Carlsson B, Dahlgren S, Karlsson J, Lindroos AK, Lönroth H, Narbro K, Näslund I, Olbers T, Svensson PA, Carlsson LM. Bariatric surgery and long-term cardiovascular events. JAMA. 2012 Jan 4;307(1):56-65. doi: 10.1001/jama.2011.1914.</citation>
    <PMID>22215166</PMID>
  </reference>
  <reference>
    <citation>Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009 Jul 30;361(5):445-54. doi: 10.1056/NEJMoa0901836.</citation>
    <PMID>19641201</PMID>
  </reference>
  <reference>
    <citation>Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012 Sep 19;308(11):1122-31.</citation>
    <PMID>22990271</PMID>
  </reference>
  <reference>
    <citation>Rubino F, Kaplan LM, Schauer PR, Cummings DE; Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010 Mar;251(3):399-405. doi: 10.1097/SLA.0b013e3181be34e7. Review.</citation>
    <PMID>19934752</PMID>
  </reference>
  <reference>
    <citation>O'Brien PE, Dixon JB, Laurie C, Skinner S, Proietto J, McNeil J, Strauss B, Marks S, Schachter L, Chapman L, Anderson M. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006 May 2;144(9):625-33.</citation>
    <PMID>16670131</PMID>
  </reference>
  <reference>
    <citation>Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, Li Z, Shekelle PG. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013 Jun 5;309(21):2250-61. doi: 10.1001/jama.2013.4851. Review.</citation>
    <PMID>23736734</PMID>
  </reference>
  <reference>
    <citation>Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014 May 22;370(21):2002-13. doi: 10.1056/NEJMoa1401329. Epub 2014 Mar 31.</citation>
    <PMID>24679060</PMID>
  </reference>
  <reference>
    <citation>Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24. Erratum in: N Engl J Med. 2014 May 8;370(19):1866.</citation>
    <PMID>23796131</PMID>
  </reference>
  <reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </reference>
  <reference>
    <citation>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.</citation>
    <PMID>9742976</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014.</citation>
    <PMID>24357209</PMID>
  </reference>
  <reference>
    <citation>CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. US Department of Health and Human Services.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Philip Schauer</investigator_full_name>
    <investigator_title>Director, Advanced Laparoscopic &amp; Bariatric Surgery; Bariatric &amp; Metabolic Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

